Tempus AI
Tempus AI is the publicly-traded precision medicine platform combining genomic sequencing with AI-driven clinical insights. NASDAQ: TEM, $8B+ market cap.
Overview
Tempus AI: AI-Powered Precision Medicine Platform
Tempus AI is AI-driven genomic and molecular sequencing with clinical context. Tempus combines genomic sequencing with the largest clinical-data corpus in oncology, making it the most data-rich AI precision-medicine platform in the US. The IPO + scale put it firmly tier-1 in healthcare AI.
Key Features
- AI-driven genomic and molecular sequencing with clinical context
- Algos for oncology decision support, cardiology, depression, diabetes
- Largest molecular-data library among diagnostics companies
- Real-world data partnerships with major pharma for trial recruitment
- Public on NASDAQ — ticker TEM, ~$8B market cap
- Founded by Eric Lefkofsky (Groupon co-founder); Chicago-based
- Powers research at top US cancer centers and academic medical institutions
Ideal Use Case
Oncologists, hematologists, and clinical researchers using Tempus diagnostics for treatment decisions — and pharma teams running real-world-evidence studies on Tempus data.
Why Use Tempus AI
Tempus combines genomic sequencing with the largest clinical-data corpus in oncology, making it the most data-rich AI precision-medicine platform in the US. The IPO + scale put it firmly tier-1 in healthcare AI.
FAQ
What does Tempus AI do? Tempus AI is a precision medicine platform that combines genomic sequencing with AI-driven clinical insights to help healthcare providers make data-informed treatment decisions. The platform analyzes patient genetic and clinical data to identify personalized treatment options.
Who should use Tempus AI? Tempus AI is designed for healthcare organizations, oncologists, and clinical teams looking to leverage genomic data and artificial intelligence to improve patient outcomes and treatment planning. It's particularly valuable for precision medicine initiatives in hospital systems and cancer care centers.
How much does Tempus AI cost? Tempus AI operates on a freemium model with both free and paid options available. Visit the Tempus AI pricing page for current plans and to inquire about costs based on your organization's needs.
How does Tempus AI compare to similar platforms? Tempus AI differentiates itself through its focus on genomic sequencing combined with AI clinical insights, while alternatives like Abridge, Flatiron Health, and Exscientia each bring different strengths to the precision medicine and healthcare AI space. Your choice depends on whether you prioritize genomic analysis, EHR integration, or drug discovery capabilities.
tl;dr
Public precision-medicine AI. Genomic sequencing + clinical insights. NASDAQ TEM.
Related
Looking for more options? Browse the Healthcare directory or read our best AI healthcare tools listicle. Tempus AI is also tracked on Crunchbase.
Why Use Tempus AI
Editorial Review
Our take on Tempus AI.
Genomic sequencing meets clinical AI; credible but narrow: precision medicine for oncology and specialized care, not a general-purpose tool.
What works
- Public company with transparent financials and regulatory scrutiny
- Combines genomics + AI in a cohesive platform; not bolt-on
- Strong community rating suggests solid execution for its niche
What doesn't
- Only valuable if you have genomic data and oncology workflows in place
- Modest engagement and non-flagship status; ecosystem still building
Tempus operates in a specific corner: combining genomic data with machine learning to surface treatment insights for cancer and rare disease. The company is publicly traded and well-capitalized, which gives it credibility and staying power. The platform ingests sequencing data and applies AI to flag clinical patterns—theoretically useful if you're a oncology center or precision medicine program with the infrastructure and volume to integrate it.
The catch is scope. This isn't a horizontal tool. You need genomic data flowing in, clinical teams trained to act on the output, and a patient population where genomic testing is already part of the standard workflow. If you're building that workflow or running a boutique genetic testing lab, it's worth a serious look. If you're a general hospital evaluating decision-support tools, you'll hit its boundaries fast.
Community rating is strong (4.93), but the tool sits outside the top-tool tier and has modest engagement (496 likes), which suggests early adoption rather than broad traction. That's not a red flag—precision medicine tools are inherently niche—but it means you're betting on a narrower ecosystem than, say, a general clinical NLP platform.
User Reviews
Similar Tools
